NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Health Care Adherence and Personalized Medicine

Mark Egan, Tomas J. Philipson

NBER Working Paper No. 20330
Issued in July 2014, Revised in September 2015
NBER Program(s):   HC   HE

Non-adherence in health care results when a patient does not initiate or continue care that a provider has recommended. Previous research identifies non-adherence as a major source of waste in US health care, totaling approximately 2.3% of GDP, and have proposed a plethora of interventions to raise adherence. However, health economics provides little explicit analyses of the important dynamic demand behavior that drives non-adherence, and it is often casually attributed to uninformed patients. We argue that whereas providers may be more informed about the population-wide effects of treatments, patients are more informed about the individual specific value of treatment. We interpret a patient’s decision to adhere to a treatment regime as an optimal stopping problem in which patients learn the value of a treatment through treatment experience. We derive strong positive and normative implications resulting from interpreting non-adherence as an optimal stopping problem. Our positive analysis derives an “adherence survival function,” depicting the share of patients still on treatment as a function of time, and predicts how various observable factors alter adherence. Our normative analysis derives the efficiency effects of non-adherence and the conditions under which adherence is too high or low. We consider the efficiency implications of this analysis for common adherence interventions. We argue that personalized medicine is intimately linked to adherence issues. It replaces the learning through treatment experience with a diagnostic test, and thereby speeds up the leaning process and cuts over-adherence and raises underadherence. We assess the quantitative implications of our analysis by calibrating the degree of over- and under-adherence for one of the largest US drug categories, cholesterol-reducing drugs. Contrary to frequent normative claims of under-adherence, our estimates suggest the efficiency loss from overadherence is over 80% larger than from under-adherence, even though only 43% of patients fully adhere.

download in pdf format
   (636 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w20330

Users who downloaded this paper also downloaded* these:
Koulayev, Skipper, and Simeonova w19496 Who Is in Control? The Determinants of Patient Adherence with Medication Therapy
Encinosa, Bernard, and Dor w15691 Does Prescription Drug Adherence Reduce Hospitalizations and Costs?
Koijen, Philipson, and Uhlig w20075 Financial Health Economics
Egan, Mulligan, and Philipson w19058 Adjusting National Accounting for Health: Is the Business Cycle Countercyclical?
Egan and Philipson w19280 International Health Economics
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us